Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Cancer Cell. 2017 Feb 13;31(2):169-171. doi: 10.1016/j.ccell.2017.01.013.

Awakening of "Schlafen11" to Tackle Chemotherapy Resistance in SCLC.

Author information

1
The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Electronic address: k.berns@nki.nl.
2
The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Electronic address: a.berns@nki.nl.

Abstract

Chemotherapy resistance arises invariably in small cell lung cancer (SCLC). In this issue of Cancer Cell, Gardner et al. find that in some SCLC, EZH2 mediates resistance via downregulation of Schlafen11 (SLFN11). Combining EZH2 inhibition with chemotherapy effectively overcomes drug resistance of xenografted SCLC, holding promise for new treatment paradigms.

PMID:
28196592
DOI:
10.1016/j.ccell.2017.01.013
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center